See also the disease-specific chapters in this Handbook for more details.





Recommended for all pregnant women at any stage of pregnancy, particularly those who will be in the 2nd or 3rd trimester during the influenza season

Clinical trial data and observational studies show no increased risk of congenital defects or adverse effects in the fetuses of women who received influenza vaccine during pregnancy. Pregnancy increases the risk of severe influenza. Influenza immunisation protects the mother, and also protects her newborn baby in the first few months after birth. See Influenza.

dTpa (diphtheria-tetanus-acellular pertussis)

Recommended as a single dose between mid 2nd trimester and early 3rd trimester of each pregnancy (ideally at 20–32 weeks)

Vaccination during pregnancy reduces the risk of pertussis in pregnant women and their young infants by 90%.1 Studies have found no evidence of an increased risk of adverse pregnancy outcomes related to pertussis vaccination during pregnancy.3-8 See Pertussis for more details.

Last updated: 
5 June 2018
Last reviewed: 
5 June 2018


diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation